TA-3166 (Megakaryocytes/platelets inducing agent) is a novel chemically synthesized c-MPL agonist (CMA) and thrombopoietin (TPO) receptor agonist. TA-316 enhances ex vivo platelet generation from human-induced pluripotent stem (iPS) cells[1][2].
TA-316 (0.01-1000 nM; 4 days) stimulates UT-7/TPO and Ba/F3-HuMpl cells proliferation, with the EC50 values of 0.3 and 0.65 nM, respectively[2].TA-316 (800 nM; 10 days) promotes biased megakaryopoiesis and upregulated MK lineage markers[2].TA-316 (200 nM; 4 days) preferentially enhances VEGFA and FGF2 expression[2].
[1]. METHOD FOR PRODUCING MEGAKARYOCYTES AND/OR PLATELETS FROM PLURIPOTENT STEM CELLS.WO2013051625A1.
[2]. Aihara A, et al. Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells. Blood Adv. 2017;1(7):468-476. Published 2017 Feb 28.